The altered gene function responsible for most tumor formation and evolution is caused by low-frequency events that are notoriously difficult to pinpoint in the genome. The Cancer Genome Analysis (CGA) Suite provides a complete workflow that addresses key issues in getting reliable, accurate results from cancer genome NGS datasets.
- The Genome Analysis Toolkit (GATK), the industry’s leading variant caller, prepares tumor/normal pair data for analysis
- MuTect, the industry’s most validated toolkit for identifying somatic point mutations in tumor/normal pairs
- ContEst for detecting cross-individual contamination levels to further improve the specificity of MuTect
- Somatic Indel Detector, a former GATK walker now available only as part of the CGA Suite
- A Perl script, test dataset, and results summary to connect, configure, and validate the workflow
- Full documentation and one-on-one, user-centered help with implementing, deploying, and applying the tools
As the foundation of the CGA Suite, MuTect provides a highly sensitive detection method that increases specificity through a series of advanced filters.
The four-step MuTect method:
- Removes low-quality sequence data
- Detects variants in tumor samples using a Bayesian classifier
- Filters data to remove false positives produced by sequencing artifacts not captured by the error model
- Employs a second Bayesian classifier to designate variants as somatic or germ-line
While other somatic mutation tools assume heterozygous, diploid events and thus provide a fixed allelic fraction, MuTect explicitly models the allelic fraction using a variant-detection statistical test that takes into account sequencing error and sequencing depth. This makes MuTect particularly sensitive to low-allelic fraction events (at or below 0.1), which is ideal for analyzing samples with low purity or complex subclonal structure.
In addition, MuTect’s specificity has been demonstrated in several collaborative studies that validated ~95% of MuTect’s calls in coding regions.
The CGA Suite complements MuTect with the Somatic Indel Detector to provide a complete picture of the potential disease-causing variants in a sample. The addition of ContEst further enhances the suite by providing a fractional contamination value to MuTect, which improves specificity. ContEst can also be used for general data quality control.
Appistry released version 2014.2 of the Cancer Genome Analysis Suite on April 21, 2014. The release includes the latest version of the GATK from Appistry, version 2014.2, based on the Broad release v.3.1-1. To learn more about the highlights of GATK v 2014.2, please visit the What’s New section of the GATK page.
Any entity using the CGA Suite in any for-profit context or to generate revenue must purchase a license from Appistry. This includes all commercial entities regardless of the nature of the work and any academic or non-profit entity charging a fee for a service that employs the CGA Suite.
The CGA Suite includes the full GATK from Appistry, which means CGA Suite customers receive all the functionality of that toolkit and all Appistry workflows, including those for non-cancer NGS analysis.
Single User and Workgroup Licenses
Academic research teams or small, start-up companies (fewer than 10 employees).
Small Business Licenses
Provides organizations of less than 50 employees with unlimited access to the GATK.
Lab, Developer, and Runtime Licenses
Research teams in organizations of greater than 50 employees who need to provide varying levels of access to the GATK.
Site and Enterprise Licenses
Scaled by organizational size and providing unlimited usage for a single geographical site or unlimited usage across all of an organization’s departments, labs, or geographies.